Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S.
Edelmann J, et al. Among authors: fischer k.
Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2.
Leukemia. 2017.
PMID: 27909343
Free PMC article.
Clinical Trial.
No abstract available.